Dual targeting strategies with bispecific antibodies

References

• Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011; 3:76 - 99; PMID: 21051951; http://dx.doi.org/10.4161/mabs.3.1.13895
   PubMed Web of Science ®Google Scholar
• Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9:767 - 774; PMID: 20811384; http://dx.doi.org/10.1038/nrd3229
   PubMed Web of Science ®Google Scholar
• Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 2006; 58:640 - 656; PMID: 16904789; http://dx.doi.org/10.1016/j.addr.2006.01.026
   PubMed Web of Science ®Google Scholar
• Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 2008; 20:460 - 470; PMID: 18656541; http://dx.doi.org/10.1016/j.coi.2008.06.012
   PubMed Web of Science ®Google Scholar
• Rothe A, Rubbert A. Recombinant proteins in rheumatology—recent advances. N Biotechnol 2011; 28:502 - 510; PMID: 21473939; http://dx.doi.org/10.1016/j.nbt.2011.03.019
   PubMed Web of Science ®Google Scholar
• Jones HE, Gee JMW, Hutcheson IR, Knowlden JM, Barrow D, Nicholson RI. Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer 2006; 13:45 - 51; PMID: 17259558; http://dx.doi.org/10.1677/erc.1.01275
   PubMed Web of Science ®Google Scholar
• van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PM, Roovers RC. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 2009; 9:748 - 760; PMID: 19754359; http://dx.doi.org/10.2174/156800909789271495
   PubMed Web of Science ®Google Scholar
• Morgillo F, Lee HY. Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist Updat 2005; 8:298 - 310; PMID: 16172017; http://dx.doi.org/10.1016/j.drup.2005.08.004
   PubMed Web of Science ®Google Scholar
• Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011; 3:273 - 288; PMID: 21393993; http://dx.doi.org/10.4161/mabs.3.3.15188
   PubMed Web of Science ®Google Scholar
• Demarest SJ, Hariharan K, Dong J. Emerging antibody combinations in oncology. MAbs 2011; 3:338 - 351; PMID: 21697653; http://dx.doi.org/10.4161/mabs.3.4.16615
   PubMed Web of Science ®Google Scholar
• Haurum JS. Recombinant polyclonal antibodies: the next generation of antibody therapeutics?. Drug Discov Today 2006; 11:655 - 660; PMID: 16793535; http://dx.doi.org/10.1016/j.drudis.2006.05.009
   PubMed Web of Science ®Google Scholar
• Koefoed K, Steinaa L, Søderberg JN, Kjær I, Jacobsen HJ, Meijer PJ, et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 2011; 3; In press PMID: 22123060
   PubMed Web of Science ®Google Scholar
• Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010; 70:588 - 597; PMID: 20068188; http://dx.doi.org/10.1158/0008-5472.CAN-09-1417
   PubMed Web of Science ®Google Scholar
• Skartved NJ, Jacobsen HJ, Pedersen MW, Jensen PF, Sen JW, Jørgensen TK, et al. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor. Clin Cancer Res 2011; 17:5962 - 5972; PMID: 21825041; http://dx.doi.org/10.1158/1078-0432.CCR-11-1209
   PubMed Web of Science ®Google Scholar
• Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301 - 316; PMID: 20414204; http://dx.doi.org/10.1038/nri2761
   PubMed Web of Science ®Google Scholar
• Müller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs 2010; 24:89 - 98; PMID: 20199124; http://dx.doi.org/10.2165/11530960-000000000-00000
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Bispecific antibodies 2011; Springer ISBN 978-3-642-20909-3
   Google Scholar
• Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 2010; 36:458 - 467; PMID: 20347527; http://dx.doi.org/10.1016/j.ctrv.2010.03.001
   PubMed Web of Science ®Google Scholar
• Graziano RF, Guptill P. Chemical production of bispecific antibodies. Methods Mol Biol 2004; 283:71 - 85; PMID: 15197303
   PubMedGoogle Scholar
• Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, et al. Chemical generation of bispecific antibodies. Proc Natl Acad Sci USA 2010; 107:22611 - 22616; PMID: 21149738
   PubMed Web of Science ®Google Scholar
• Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 1997; 15:159 - 163; PMID: 9035142; http://dx.doi.org/10.1038/nbt0297-159
   PubMed Web of Science ®Google Scholar
• Orcutt KD, Ackerman ME, Cieslewicz M, Quiroz E, Slusarczyk AL, Frangioni JV, et al. A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel 2010; 23:221 - 228; PMID: 20019028; http://dx.doi.org/10.1093/protein/gzp077
   PubMed Web of Science ®Google Scholar
• Dong J, Sereno A, Snyder WB, Miller BR, Tamraz S, Doern A, et al. Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem 2011; 286:4703 - 4717; PMID: 21123183; http://dx.doi.org/10.1074/jbc.M110.184317
   PubMed Web of Science ®Google Scholar
• Schanzer J, Jekle A, Nezu J, Lochner A, Croasdale R, Dioszegi M, et al. Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains. Antimicrob Agents Chemother 2011; 55:2369 - 2378; PMID: 21300827; http://dx.doi.org/10.1128/AAC.00215-10
   PubMed Web of Science ®Google Scholar
• Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290 - 1297; PMID: 17934452; http://dx.doi.org/10.1038/nbt1345
   PubMed Web of Science ®Google Scholar
• Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323:1610 - 1614; PMID: 19299620; http://dx.doi.org/10.1126/science.1165480
   PubMed Web of Science ®Google Scholar
• Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschläger M, Antes B, et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel 2010; 23:289 - 297; PMID: 20150180; http://dx.doi.org/10.1093/protein/gzq005
   PubMed Web of Science ®Google Scholar
• Ridgway JB, Presta LG, Carter P. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617 - 621; PMID: 8844834; http://dx.doi.org/10.1093/protein/9.7.617
   PubMedGoogle Scholar
• Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, et al. An efficient route to human bispecific IgG. Nat Biotechnol 1998; 16:677 - 681; PMID: 9661204; http://dx.doi.org/10.1038/nbt0798677
   PubMed Web of Science ®Google Scholar
• Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA 2011; 108:11187 - 11192; PMID: 21690412; http://dx.doi.org/10.1073/pnas.1019002108
   PubMed Web of Science ®Google Scholar
• Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem 2010; 285:19637 - 19646; PMID: 20400508; http://dx.doi.org/10.1074/jbc.M110.117382
   PubMed Web of Science ®Google Scholar
• Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 2010; 23:195 - 202; PMID: 20299542; http://dx.doi.org/10.1093/protein/gzp094
   PubMed Web of Science ®Google Scholar
• Moore GL, Bautista C, Pong E, Nguyen DHT, Jacinto J, Eivazi A, et al. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs 2011; 3; In press PMID: 22123055
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Alternative antibody formats. Curr Opin Mol Ther 2010; 12:176 - 183; PMID: 20373261
   PubMed Web of Science ®Google Scholar
• Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H, et al. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J Immunother 2008; 31:871 - 884; PMID: 18833000; http://dx.doi.org/10.1097/CJI.0b013e318186c8b4
   PubMed Web of Science ®Google Scholar
• Holliger P, Prospero T, Winter G. “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90:6444 - 6448; PMID: 8341653; http://dx.doi.org/10.1073/pnas.90.14.6444
   PubMed Web of Science ®Google Scholar
• FitzGerald K, Holliger P, Winter G. Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. Protein Eng 1997; 10:1221 - 1225; PMID: 9488147; http://dx.doi.org/10.1093/protein/10.10.1221
   PubMedGoogle Scholar
• Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, et al. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol 2010; 399:436 - 449; PMID: 20382161; http://dx.doi.org/10.1016/j.jmb.2010.04.001
   PubMed Web of Science ®Google Scholar
• Brüsselbach S, Korn T, Völkel T, Müller R, Kontermann RE. Enzyme recruitment and tumor cell killing in vitro by a secreted bispecific single-chain diabody. Tumor Targeting 1999; 4:115 - 123
   Google Scholar
• Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER, et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 1999; 293:41 - 56; PMID: 10512714; http://dx.doi.org/10.1006/jmbi.1999.3156
   PubMed Web of Science ®Google Scholar
• Schoonjans R, Willems A, Schoonooghe S, Leoen J, Grooten J, Mertens N. A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain. Biomol Eng 2001; 17:193 - 202; PMID: 11337278; http://dx.doi.org/10.1016/S1389-0344(01)00066-1
   PubMedGoogle Scholar
• Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 2008; 49:158 - 163; PMID: 18077530; http://dx.doi.org/10.2967/jnumed.107.046185
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 2009; 23:93 - 109; PMID: 19489651; http://dx.doi.org/10.2165/00063030-200923020-00003
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011; Epub ahead of print PMID: 21862310
   PubMed Web of Science ®Google Scholar
• Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 2008; 65:1566 - 1584; PMID: 18259690; http://dx.doi.org/10.1007/s00018-008-7440-8
   PubMed Web of Science ®Google Scholar
• Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer. Nat Clin Pract Oncol 2007; 4:591 - 602; PMID: 17898809; http://dx.doi.org/10.1038/ncponc0934
   PubMedGoogle Scholar
• Ludovini V, Bellezza G, Pistola L, Bianconi F, Di Carlo L, Sidoni A, et al. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 2009; 20:842 - 849; PMID: 19153117; http://dx.doi.org/10.1093/annonc/mdn727
   PubMed Web of Science ®Google Scholar
• Ueda S, Hatsuse K, Tsuda H, Ogata S, Kawarabayashi N, Takigawa T, et al. Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. Mod Pathol 2006; 19:788 - 796; PMID: 16575403
   PubMed Web of Science ®Google Scholar
• Lu D, Zhang H, Ludwig D, Persaud A, Jimenez X, Burtrum D, et al. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 2004; 279:2856 - 2865; PMID: 14576153; http://dx.doi.org/10.1074/jbc.M310132200
   PubMed Web of Science ®Google Scholar
• Lu D, Jimenez X, Witte L, Zhu Z. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody. Biochem Biophys Res Commun 2004; 318:507 - 513; PMID: 15120630; http://dx.doi.org/10.1016/j.bbrc.2004.04.060
   PubMed Web of Science ®Google Scholar
• Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005; 280:19665 - 19672; PMID: 15757893; http://dx.doi.org/10.1074/jbc.M500815200
   PubMed Web of Science ®Google Scholar
• Emanuel SL, Engle LJ, Chao G, Zhu RR, Cao C, Lin Z, et al. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. MAbs 2011; 3:38 - 48; PMID: 21099371; http://dx.doi.org/10.4161/mabs.3.1.14168
   PubMed Web of Science ®Google Scholar
• Nielsen U, Huhalov A, Harms B, Paragas V, Adams S, Gu J, et al. MM-111: a novel bispecific antibody targeting ErbB3 with potent anti-tumor activity in ErbB2 overexpressing malignancies. Cancer Res 2009; 69:4166
   Google Scholar
• Shen J, Vil MD, Jimenez X, Zhang H, Iacolina M, Mangalampalli V, et al. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies. J Immunol Methods 2007; 318:65 - 74; PMID: 17126853; http://dx.doi.org/10.1016/j.jim.2006.09.020
   PubMed Web of Science ®Google Scholar
• Yu J, Ustach C, Kim HRC. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 2003; 36:49 - 59; PMID: 12542975; http://dx.doi.org/10.5483/BMBRep.2003.36.1.049
   PubMedGoogle Scholar
• Board R, Jayson GC. Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. Drug Resist Updat 2005; 8:75 - 83; PMID: 15939344; http://dx.doi.org/10.1016/j.drup.2005.03.004
   PubMed Web of Science ®Google Scholar
• Shen J, Vil MD, Jimenez X, Iacolina M, Zhang H, Zhu Z. Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies. J Biol Chem 2006; 281:10706 - 10714; PMID: 16481314; http://dx.doi.org/10.1074/jbc.M513415200
   PubMed Web of Science ®Google Scholar
• Tugues S, Koch S, Gualandi L, Li X, Claesson-Welsh L. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med 2011; 32:88 - 111; PMID: 21565214; http://dx.doi.org/10.1016/j.mam.2011.04.004
   PubMed Web of Science ®Google Scholar
• Jimenez X, Lu D, Brennan L, Persaud K, Liu M, Miao H, et al. A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3. Mol Cancer Ther 2005; 4:427 - 434; PMID: 15767551
   PubMed Web of Science ®Google Scholar
• Lu D, Jimenez X, Zhang H, Atkins A, Brennan L, Balderes P, et al. Di-diabody: a novel tetravalent bispecific antibody molecule by design. J Immunol Methods 2003; 279:219 - 232; PMID: 12969563; http://dx.doi.org/10.1016/S0022-1759(03)00251-5
   PubMed Web of Science ®Google Scholar
• Leonard JP, Schuster SJ, Emmanouilides C, Couture F, Teoh N, Wegener WA, et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 2008; 113:2714 - 2723; PMID: 18853418; http://dx.doi.org/10.1002/cncr.23890
   PubMed Web of Science ®Google Scholar
• Qu Z, Goldenberg DM, Cardillo TM, Shi V, Hansen HJ, Chang CH. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood 2008; 111:2211 - 2219; PMID: 18025153; http://dx.doi.org/10.1182/blood-2007-08-110072
   PubMed Web of Science ®Google Scholar
• Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood 2009; 113:6161 - 6171; PMID: 19372261; http://dx.doi.org/10.1182/blood-2008-10-187138
   PubMed Web of Science ®Google Scholar
• Gupta P, Goldenberg DM, Rossi EA, Chang CH. Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. Blood 2010; 116:3258 - 3267; PMID: 20628151; http://dx.doi.org/10.1182/blood-2010-03-276857
   PubMed Web of Science ®Google Scholar
• Tuscano JM, Ma Y, Martin SM, Kato J, O'Donnell RT. The Bs20 × 22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone. Cancer Immunol Immunother 2011; 60:771 - 780; PMID: 21347809; http://dx.doi.org/10.1007/s00262-011-0978-6
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008; 26:3621 - 3630; PMID: 18640940; http://dx.doi.org/10.1200/JCO.2007.15.7198
   PubMed Web of Science ®Google Scholar
• Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. MAbs 2009; 1:128 - 141; PMID: 20061822; http://dx.doi.org/10.4161/mabs.1.2.7631
   PubMed Web of Science ®Google Scholar
• Looney RJ. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis. Rheumatology (Oxford) 2005; 44:13 - 17; PMID: 15851522; http://dx.doi.org/10.1093/rheumatology/keh618
   PubMed Web of Science ®Google Scholar
• Edwards JCW, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 2006; 20:915 - 928; PMID: 16980214; http://dx.doi.org/10.1016/j.berh.2006.05.010
   PubMed Web of Science ®Google Scholar
• Cohen SB. Targeting the B cell in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2010; 24:553 - 563; PMID: 20732652; http://dx.doi.org/10.1016/j.berh.2009.11.006
   PubMed Web of Science ®Google Scholar
• Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol 2010; 10:328 - 343; PMID: 20414206; http://dx.doi.org/10.1038/nri2762
   PubMed Web of Science ®Google Scholar
• Veri MC, Burke S, Huang L, Li H, Gorlatov S, Tuaillon N, et al. Therapeutic control of B cell activation via recruitment of Fcγ receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum (Munch) 2010; 62:1933 - 1943
   PubMed Web of Science ®Google Scholar
• Zhang K, Kepley CL, Terada T, Zhu D, Perez H, Saxon A. Inhibition of allergen-specific IgE reactivity by a human Ig Fcgamma-Fcepsilon bifunctional fusion protein. J Allergy Clin Immunol 2004; 114:321 - 327; PMID: 15316510; http://dx.doi.org/10.1016/j.jaci.2004.03.058
   PubMed Web of Science ®Google Scholar
• Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, et al. Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem 2010; 285:20850 - 20859; PMID: 20444694; http://dx.doi.org/10.1074/jbc.M110.113910
   PubMed Web of Science ®Google Scholar
• Tam SW, Demissie S, Thomas D, Daëron M. A bispecific antibody against human IgE and human FcgammaRII that inhibits antigen-induced histamine release by human mast cells and basophils. Allergy 2004; 59:772 - 780; PMID: 15180766; http://dx.doi.org/10.1111/j.1398-9995.2004.00332.x
   PubMed Web of Science ®Google Scholar
• Saylor C, Dadachova E, Casadevall A. Monoclonal antibody-based therapies for microbial diseases. Vaccine 2009; 27:38 - 46; PMID: 20006139
   PubMed Web of Science ®Google Scholar
• Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004; 2:695 - 703; PMID: 15372080; http://dx.doi.org/10.1038/nrmicro974
   PubMed Web of Science ®Google Scholar
• Lim CS, Rosli R, Seow HF, Chong PP. Candida and invasive candidiasis: back to basics. Eur J Clin Microbiol Infect Dis 2911; Epub ahead of print PMID: 21544694
   PubMed Web of Science ®Google Scholar
• De Bernardis F, Liu H, O'Mahony R, La Valle R, Bartollino S, Sandini S, et al. Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J Infect Dis 2007; 195:149 - 157; PMID: 17152019; http://dx.doi.org/10.1086/509891
   PubMed Web of Science ®Google Scholar
• Dong J, Demarest SJ, Sereno A, Tamraz S, Langley E, Doern A, et al. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol Cancer Ther 2010; 9:2593 - 2604; PMID: 20716637; http://dx.doi.org/10.1158/1535-7163.MCT-09-1018
   PubMed Web of Science ®Google Scholar
• Eggel A, Baumann MJ, Amstutz P, Stadler BM, Vogel M. DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage. J Mol Biol 2009; 393:598 - 607; PMID: 19683003; http://dx.doi.org/10.1016/j.jmb.2009.08.014
   PubMed Web of Science ®Google Scholar
• Thomson NC, Chaudhuri R, Spears M. Emerging therapies for severe asthma. BMC Med 2011; 9:102; PMID: 21896202; http://dx.doi.org/10.1186/1741-7015-9-102
   PubMed Web of Science ®Google Scholar
• Nowak D. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. Respir Med 2006; 100:1907 - 1917; PMID: 16949266; http://dx.doi.org/10.1016/j.rmed.2005.10.004
   PubMed Web of Science ®Google Scholar
• Laventie BJ, Rademaker HJ, Saleh M, de Boer E, Janssens R, Bourcier T, et al. Heavy chain-only antibodies and tetravalent bispecific antibody neutralizing Staphylococcus aureus leukotoxins. Proc Natl Acad Sci USA 2011; 108:16404 - 16409; PMID: 21930905; http://dx.doi.org/10.1073/pnas.1102265108
   PubMed Web of Science ®Google Scholar
• Hmila I, Saerens D, Ben Abderrazek R, Vincke C, Abidi N, Benlasfar Z, et al. A bispecific nanobody to provide full protection against lethal scorpion envenoming. FASEB J 2010; 24:3479 - 3489; PMID: 20410443; http://dx.doi.org/10.1096/fj.09-148213
   PubMed Web of Science ®Google Scholar
• Hammoudi-Triki D, Lefort J, Rougeot C, Robbe-Vincent A, Bon C, Laraba-Djebari F, et al. Toxicokinetic and toxicodynamic analyses of Androctonus australis hector venom in rats: optimization of antivenom therapy. Toxicol Appl Pharmacol 2007; 218:205 - 214; PMID: 17198719; http://dx.doi.org/10.1016/j.taap.2006.11.003
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249 - 257; PMID: 11001068; http://dx.doi.org/10.1038/35025220
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25:581 - 611; PMID: 15294883; http://dx.doi.org/10.1210/er.2003-0027
   PubMed Web of Science ®Google Scholar
• Kou G, Shi J, Chen L, Zhang D, Hou S, Zhao L, et al. A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin. Cancer Lett 2010; 299:130 - 136; PMID: 20826049; http://dx.doi.org/10.1016/j.canlet.2010.08.011
   PubMed Web of Science ®Google Scholar
• Rader C, Sinha SC, Popkov M, Lerner RA, Barbas CF 3rd. Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst. Proc Natl Acad Sci USA 2003; 100:5396 - 5400; PMID: 12702756; http://dx.doi.org/10.1073/pnas.0931308100
   PubMed Web of Science ®Google Scholar
• Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007; 66:228 - 234; PMID: 16935912; http://dx.doi.org/10.1136/ard.2006.055111
   PubMed Web of Science ®Google Scholar
• Wu C, Ying H, Bose S, Miller R, Medina L, Santora L, et al. Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs 2009; 1:339 - 347; PMID: 20068402; http://dx.doi.org/10.4161/mabs.1.4.8755
   PubMed Web of Science ®Google Scholar
• Mabry R, Lewis KE, Moore M, McKernan PA, Bukowski TR, Bontadelli K, et al. Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Protein Eng Des Sel 2010; 23:115 - 127; PMID: 20022918; http://dx.doi.org/10.1093/protein/gzp073
   PubMed Web of Science ®Google Scholar
• McGeachy MJ, Cua DJ. Th17 cell differentiation: the long and winding road. Immunity 2008; 28:445 - 453; PMID: 18400187; http://dx.doi.org/10.1016/j.immuni.2008.03.001
   PubMed Web of Science ®Google Scholar
• Cornelissen F, van Hamburg JP, Lubberts E. The IL-12/IL-23 axis and its role in Th17 cell development, pathology and plasticity in arthritis. Curr Opin Investig Drugs 2009; 10:452 - 462; PMID: 19431078
   PubMed Web of Science ®Google Scholar
• Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, et al. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 2008; 7:3747 - 3758; PMID: 19029832; http://dx.doi.org/10.4161/cc.7.23.7212
   PubMed Web of Science ®Google Scholar
• Yang W, Klos K, Yang Y, Smith TL, Shi D, Yu D. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C and D in human breast carcinoma. Cancer 2002; 94:2855 - 2861; PMID: 12115372; http://dx.doi.org/10.1002/cncr.10553
   PubMed Web of Science ®Google Scholar
• Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004; 18:338 - 340; PMID: 14657001
   PubMed Web of Science ®Google Scholar
• Shen J, Vil MD, Zhang H, Tonra JR, Rong LL, Damoci C, et al. An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody. Biochem Biophys Res Commun 2007; 357:1142 - 1147; PMID: 17462601; http://dx.doi.org/10.1016/j.bbrc.2007.04.075
   PubMed Web of Science ®Google Scholar
• Mabry R, Gilbertson DG, Frank A, Vu T, Ardourel D, Ostrander C, et al. A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo. MAbs 2010; 2:20 - 34; PMID: 20065654; http://dx.doi.org/10.4161/mabs.2.1.10498
   PubMed Web of Science ®Google Scholar
• Lum LG, Davol PA. Retargeting T cells and immune effector cells with bispecific antibodies. Cancer Chemother Biol Response Modif 2005; 22:273 - 291; PMID: 16110617
   PubMedGoogle Scholar
• Müller D, Kontermann RE. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr Opin Mol Ther 2007; 9:319 - 326; PMID: 17694444
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974 - 977; PMID: 18703743; http://dx.doi.org/10.1126/science.1158545
   PubMed Web of Science ®Google Scholar
• Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29:2493 - 2498; PMID: 21576633; http://dx.doi.org/10.1200/JCO.2010.32.7270
   PubMed Web of Science ®Google Scholar
• Kügler M, Stein C, Kellner C, Mentz K, Saul D, Schwenkert M, et al. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol 2010; 150:574 - 586; PMID: 20636437; http://dx.doi.org/10.1111/j.1365-2141.2010.08300.x
   PubMed Web of Science ®Google Scholar
• Schubert I, Kellner C, Stein C, Kügler M, Schwenkert M, Saul D, et al. A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting. MAbs 2011; 3:21 - 30; PMID: 21081841; http://dx.doi.org/10.4161/mabs.3.1.14057
   PubMed Web of Science ®Google Scholar
• Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007; 58:221 - 237; PMID: 17059365; http://dx.doi.org/10.1146/annurev.med.58.070605.115320
   PubMed Web of Science ®Google Scholar
• Choudhary S, Mathew M, Verma RS. Therapeutic potential of anticancer immunotoxins. Drug Discov Today 2011; 16:495 - 503; PMID: 21511052; http://dx.doi.org/10.1016/j.drudis.2011.04.003
   PubMed Web of Science ®Google Scholar
• Manoukian G, Hagemeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther 2009; 9:1445 - 1451; PMID: 19817678; http://dx.doi.org/10.1517/14712590903348135
   PubMed Web of Science ®Google Scholar
• Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ, et al. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci USA 2011; 108:5742 - 5747; PMID: 21436054; http://dx.doi.org/10.1073/pnas.1102746108
   PubMed Web of Science ®Google Scholar
• Frankel AE, Woo JH. Bispecific immunotoxins. Leuk Res 2009; 33:1173 - 1174; PMID: 19406472; http://dx.doi.org/10.1016/j.leukres.2009.03.037
   PubMed Web of Science ®Google Scholar
• Duke-Cohan JS, Morimoto C, Schlossman SF. Targeting of an activated T-cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD26. Blood 1993; 82:2224 - 2234; PMID: 8104537
   PubMed Web of Science ®Google Scholar
• Duke-Cohan JS, Morimoto C, Schlossman SF. Depletion of the helper/inducer (memory) T cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD29. Transplantation 1993; 56:1188 - 1196; PMID: 7504344; http://dx.doi.org/10.1097/00007890-199311000-00027
   PubMed Web of Science ®Google Scholar
• Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin Cancer Res 2005; 11:3879 - 3888; PMID: 15897589; http://dx.doi.org/10.1158/1078-0432.CCR-04-2290
   PubMed Web of Science ®Google Scholar
• Vallera DA, Chen H, Sicheneder AR, Panoskaltsis-Mortari A, Taras EP. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res 2009; 33:1233 - 1242; PMID: 19327829; http://dx.doi.org/10.1016/j.leukres.2009.02.006
   PubMed Web of Science ®Google Scholar
• Vallera DA, Oh S, Chen H, Shu Y, Frankel AE. Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases. Mol Cancer Ther 2010; 9:1872 - 1883; PMID: 20530709; http://dx.doi.org/10.1158/1535-7163.MCT-10-0203
   PubMed Web of Science ®Google Scholar
• Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin Cancer Res 2007; 13:3058 - 3067; PMID: 17505009; http://dx.doi.org/10.1158/1078-0432.CCR-06-2454
   PubMed Web of Science ®Google Scholar
• Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA. A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer. Clin Cancer Res 2007; 13:6486 - 6493; PMID: 17975161; http://dx.doi.org/10.1158/1078-0432.CCR-07-0938
   PubMed Web of Science ®Google Scholar
• Stish BJ, Oh S, Vallera DA. Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model. J Neurooncol 2008; 87:51 - 61; PMID: 18084721; http://dx.doi.org/10.1007/s11060-007-9499-8
   PubMed Web of Science ®Google Scholar
• Vallera DA, Stish BJ, Shu Y, Chen H, Saluja A, Buchsbaum DJ, et al. Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model. Gut 2008; 57:634 - 641; PMID: 18222985; http://dx.doi.org/10.1136/gut.2007.137802
   PubMed Web of Science ®Google Scholar
• Oh S, Ohlfest JR, Todhunter DA, Vallera VD, Hall WA, Chen H, et al. Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery. J Neurooncol 2009; 95:331 - 342; PMID: 19517064; http://dx.doi.org/10.1007/s11060-009-9932-2
   PubMed Web of Science ®Google Scholar
• Oh S, Stish BJ, Vickers SM, Buchsbaum DJ, Saluja AK, Vallera DA. A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer. Pancreas 2010; 39:913 - 922; PMID: 20182395; http://dx.doi.org/10.1097/MPA.0b013e3181cbd908
   PubMed Web of Science ®Google Scholar
• Todhunter DA, Hall WA, Rustamzadeh E, Shu Y, Doumbia SO, Vallera DA. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng Des Sel 2004; 17:157 - 164; PMID: 15047912; http://dx.doi.org/10.1093/protein/gzh023
   PubMed Web of Science ®Google Scholar
• Hall WA, Vallera DA. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme. Neurosurg Focus 2006; 20:23; PMID: 16709029; http://dx.doi.org/10.3171/foc.2006.20.4.15
   PubMedGoogle Scholar
• Rustamzadeh E, Vallera DA, Todhunter DA, Low WC, Panoskaltsis-Mortari A, Hall WA. Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13. J Neurooncol 2006; 77:257 - 266; PMID: 16314943; http://dx.doi.org/10.1007/s11060-005-9051-7
   PubMed Web of Science ®Google Scholar
• Oh S, Stish BH, Sachdev D, Chen H, Dudek AZ, Vallera DA. A novel “reduced immunogenicity” bispecific targeted toxin simultaneously recognizing human EGF and IL-4 receptors in a mouse model of metastatic breast carcinoma. Clin Cancer Res 2009; 15:6137 - 6147; PMID: 19789305; http://dx.doi.org/10.1158/1078-0432.CCR-09-0696
   PubMed Web of Science ®Google Scholar
• Stish BJ, Oh S, Chen H, Dudek AZ, Kratzke RA, Vallera DA. Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. Br J Cancer 2009; 101:1114 - 1123; PMID: 19755995; http://dx.doi.org/10.1038/sj.bjc.6605297
   PubMed Web of Science ®Google Scholar
• Tsai AK, Oh S, Chen H, Shu Y, Ohlfest JR, Vallera DA. A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature. J Neurooncol 2011; 103:255 - 266; PMID: 20830604; http://dx.doi.org/10.1007/s11060-010-0392-5
   PubMed Web of Science ®Google Scholar
• Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009; 27:83 - 117; PMID: 19007331; http://dx.doi.org/10.1146/annurev.immunol.021908.132544
   PubMed Web of Science ®Google Scholar
• Ortiz-Sánchez E, Helguera G, Daniels TR, Penichet ML. Antibody-cytokine fusion proteins: applications in cancer therapy. Expert Opin Biol Ther 2008; 8:609 - 632; PMID: 18407765; http://dx.doi.org/10.1517/14712598.8.5.609
   PubMed Web of Science ®Google Scholar
• Rudman SM, Jameson MB, McKeage MJ, Savage P, Jodrell DI, Harries M, et al. A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res 2011; 17:1998 - 2005; PMID: 21447719; http://dx.doi.org/10.1158/1078-0432.CCR-10-2490
   PubMed Web of Science ®Google Scholar
• Rossi EA, Rossi DL, Stein R, Goldenberg DM, Chang CH. A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells. Cancer Res 2010; 70:7600 - 7609; PMID: 20876805; http://dx.doi.org/10.1158/0008-5472.CAN-10-2126
   PubMed Web of Science ®Google Scholar
• Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008; 14:1310 - 1316; PMID: 18316549; http://dx.doi.org/10.1158/1078-0432.CCR-07-1441
   PubMed Web of Science ®Google Scholar
• Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009; 30:592 - 599; PMID: 19837467; http://dx.doi.org/10.1016/j.tips.2009.08.004
   PubMed Web of Science ®Google Scholar
• Fenske DB, Cullis PR. Liposomal nanomedicines. Expert Opin Drug Deliv 2008; 5:25 - 44; PMID: 18095927; http://dx.doi.org/10.1517/17425247.5.1.25
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007; 2:751 - 760; PMID: 18654426; http://dx.doi.org/10.1038/nnano.2007.387
   PubMed Web of Science ®Google Scholar
• Markman M. Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. Cancer Manag Res 2011; 3:219 - 225; PMID: 21792330; http://dx.doi.org/10.2147/CMAR.S15558
   PubMedGoogle Scholar
• Kontermann RE. Immunoliposomes for cancer therapy. Curr Opin Mol Ther 2006; 8:39 - 45; PMID: 16506524
   PubMed Web of Science ®Google Scholar
• Torchilin V. Antibody-modified liposomes for cancer chemotherapy. Expert Opin Drug Deliv 2008; 5:1003 - 1025; PMID: 18754750; http://dx.doi.org/10.1517/17425247.5.9.1003
   PubMed Web of Science ®Google Scholar
• Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006; 66:6732 - 6740; PMID: 16818648; http://dx.doi.org/10.1158/0008-5472.CAN-05-4199
   PubMed Web of Science ®Google Scholar
• Park JW, Benz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 2004; 31:196 - 205; PMID: 15717745; http://dx.doi.org/10.1053/j.seminoncol.2004.08.009
   PubMed Web of Science ®Google Scholar
• Karanth H, Murthy RS. pH-sensitive liposomes—principle and application in cancer therapy. J Pharm Pharmacol 2007; 59:469 - 483; PMID: 17430630; http://dx.doi.org/10.1211/jpp.59.4.0001
   PubMed Web of Science ®Google Scholar
• Koning GA, Morselt HW, Gorter A, Allen TM, Zalipsky S, Scherphof GL, et al. Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparison. Pharm Res 2003; 20:1249 - 1257; PMID: 12948023; http://dx.doi.org/10.1023/A:1025009300562
   PubMed Web of Science ®Google Scholar
• Nellis DF, Ekstrom DL, Kirpotin DB, Zhu J, Andersson R, Broadt TL, et al. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog 2005; 21:205 - 220; PMID: 15903260; http://dx.doi.org/10.1021/bp049840y
   PubMed Web of Science ®Google Scholar
• Mumbengegwi DL, Allen TM. Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity. Biochim Biophys Acta 2005; 1711:25 - 32; PMID: 15904660
   PubMed Web of Science ®Google Scholar
• Saul JM, Annapragada AV, Bellamkonda RV. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release 2006; 114:277 - 287; PMID: 16904220; http://dx.doi.org/10.1016/j.jconrel.2006.05.028
   PubMed Web of Science ®Google Scholar
• Quan CY, Chang C, Wei H, Chen CS, Xu XD, Cheng SX, et al. Dual targeting of a thermosensitive nanogel conjugated with transferrin and RGD-containing peptide for effective cell uptake and drug release. Nanotechnology 2009; 20:335101; PMID: 19636104; http://dx.doi.org/10.1088/0957-4484/20/33/335101
   PubMed Web of Science ®Google Scholar
• Meng S, Su B, Li W, Ding Y, Tang L, Zhou W, et al. Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes. Nanotechnology 2010; 21:415103; PMID: 20852356; http://dx.doi.org/10.1088/0957-4484/21/41/415103
   PubMed Web of Science ®Google Scholar
• Kluza E, van der Schaft DWJ, Hautvast PAI, Mulder WJM, Mayo KH, Griffioen AW, et al. Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett 2010; 10:52 - 58; PMID: 19968235; http://dx.doi.org/10.1021/nl902659g
   PubMed Web of Science ®Google Scholar
• Murase Y, Asai T, Katanasaka Y, Sugiyama T, Shimizu K, Maeda N, et al. A novel DDS strategy, “dual-targeting”, and its application for antineovascular therapy. Cancer Lett 2010; 287:165 - 171; PMID: 19616372; http://dx.doi.org/10.1016/j.canlet.2009.06.008
   PubMed Web of Science ®Google Scholar
• Friedman M, Lindström S, Ekerljung L, Andersson-Svahn H, Carlsson J, Brismar H, et al. Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule. Biotechnol Appl Biochem 2009; 54:121 - 131; PMID: 19492986; http://dx.doi.org/10.1042/BA20090096
   PubMed Web of Science ®Google Scholar